{
    "nct_id": "NCT05153174",
    "official_title": "Safety, Feasibility and Efficacy of Sulforaphane (Avmacol) in Chronic Kidney Disease",
    "inclusion_criteria": "* eGFR ≥ 20 and <60 ml/min/m2/year, and a decline in eGFR of ≥ 3 ml/min/m2/year in the previous 12 months\n* Blood pressure <140/90 mm Hg prior to initiation of sulphoraphane\n* stable anti-hypertensive regimen for at least one month prior to initiation of sulphoraphane or successful run-in period\n* able to provide consent\n* able to swallow capsules\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 80 Years",
    "exclusion_criteria": "* significant co-morbid conditions with life expectancy of <1 year\n* uncontrolled hypertension\n* serum potassium of >5.5 mEq/L at screening\n* New York Heart Association Class 3 or 4 heart failure symptoms, known EF ≤30% or hospital admission for heart failure within the past 3 months\n* factors judged to limit adherence to interventions\n* current participation in another study\n* pregnancy or planning to become pregnant or currently breastfeeding\n* history of dementia\n* on anticoagulants or immunosuppression\n* under treatment for cancer",
    "miscellaneous_criteria": ""
}